Table 1.

Panel of clinical cases reported in the literature treated with gilteritinib, as described in the text. AML = acute myeloid leukemia; MRC-AML = myelodysplasia-related-change AML; t-AML = therapy-related AML; wt = wild type; HSCT = hematopoietic stem cell transplant; DLI = donor lymphocyte infusion; HDAC = high-dose Ara-C; CR = complete remission; PR = partial remission.

Case No.	Patient Features at AML Diagnosis	Previous Treatments for AML	MS Localization	MS Onset	MS Therapies	Outcome
1	56-year-old patient affected by FLT3-ITD-mutated AML	Cytarabine/anthracycline induction scheme and HSCT	Subcutaneous all over the soma	On day +180 from HSCT	Etoposide and ranimustine, Gilteritinib	Complete disappearance of skin disease
2	38-year-old patient with diagnosis of FLT3-ITD-mutated MRC-AML	Cytarabine/anthracycline induction scheme and HSCT, DLI	Supraclavicular mass	On day +400 from HSCT	Gilteritinib	New CR in the bone marrow and extramedullary involvement, second HSCT administration
3	Patient affected by NPM1 and FLT3-ITD-mutated t-AML	CPX-351 for induction and consolidation therapy	Cerebrospinal fluid and meningeal	During follow-up after the end of consolidation therapy	FLA-Ida and medicated LP, Gilteritinib	Complete regression of meningeal relapse, PR in bone marrow re-evaluation
4	60-year-old patient affected by FLT3-ITD-mutated AML involving the skin	Cytarabine/anthracycline induction scheme	Irido-cilio-choroidal	During consolidation therapy	Gilteritinib	Complete regression of extramedullary involvement and improvement of visual acuity, but a contemporary progression of AML, leading to patient death
5	47-year-old patient affected by NPM1-mut and FLT3 wt AML	Cytarabine/anthracycline induction scheme and four consolidation cycles of HDAC, clinical trial and HSCT, sorafenib, and azacytidine caused FLT3+ relapse	Vaginal and bilateral breast masses	In third overall FLT3+ AML relapse, second after HSCT	Gilteritinib	Fourth CR and second HSCT administration